$AVTE
Aerovate Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000179874924000059 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.082M
YoY Change 58.08%
% of Gross Profit
Research & Development $10.33M
YoY Change -38.83%
% of Gross Profit
Depreciation & Amortization $218.0K
YoY Change 626.67%
% of Gross Profit
Operating Expenses $17.41M
YoY Change -18.52%
Operating Profit -$17.41M
YoY Change -18.52%
Interest Expense $1.183M
YoY Change -34.42%
% of Operating Profit
Other Income/Expense, Net $1.173M
YoY Change -35.01%
Pretax Income -$16.24M
YoY Change -16.99%
Income Tax
% Of Pretax Income
Net Earnings -$16.24M
YoY Change -17.0%
Net Earnings / Revenue
Basic Earnings Per Share -$0.56
Diluted Earnings Per Share -$0.56
COMMON SHARES
Basic Shares Outstanding 28.87M 28.87M
Diluted Shares Outstanding 28.86M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $88.73M
YoY Change -34.37%
Cash & Equivalents $31.12M
Short-Term Investments $57.62M
Other Short-Term Assets $1.875M
YoY Change -21.88%
Inventory
Prepaid Expenses $993.0K
Receivables
Other Receivables
Total Short-Term Assets $90.61M
YoY Change -34.15%
LONG-TERM ASSETS
Property, Plant & Equipment $14.00K
YoY Change -95.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $81.00K
YoY Change -96.39%
Total Long-Term Assets $354.0K
YoY Change -89.18%
TOTAL ASSETS
Total Short-Term Assets $90.61M
Total Long-Term Assets $354.0K
Total Assets $90.96M
YoY Change -35.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $908.0K
YoY Change -74.09%
Accrued Expenses $8.414M
YoY Change -22.09%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.32M
YoY Change -29.95%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $151.0K
YoY Change -62.25%
Total Long-Term Liabilities $151.0K
YoY Change -62.25%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.32M
Total Long-Term Liabilities $151.0K
Total Liabilities $10.47M
YoY Change -30.93%
SHAREHOLDERS EQUITY
Retained Earnings -$227.6M
YoY Change 59.16%
Common Stock $3.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $80.49M
YoY Change
Total Liabilities & Shareholders Equity $90.96M
YoY Change -35.43%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$16.24M
YoY Change -17.0%
Depreciation, Depletion And Amortization $218.0K
YoY Change 626.67%
Cash From Operating Activities -$16.04M
YoY Change 2.77%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $16.07M
YoY Change -222.74%
Cash From Investing Activities $16.07M
YoY Change -222.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 22.00K
YoY Change 10.0%
NET CHANGE
Cash From Operating Activities -16.04M
Cash From Investing Activities 16.07M
Cash From Financing Activities 22.00K
Net Change In Cash 46.00K
YoY Change -100.16%
FREE CASH FLOW
Cash From Operating Activities -$16.04M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
dei Entity Central Index Key
EntityCentralIndexKey
0001798749
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28867711
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27762703
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#ShortTermInvestments
CY2023Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#ShortTermInvestments
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40544
dei Entity Registrant Name
EntityRegistrantName
AEROVATE THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1377888
dei Entity Address Address Line1
EntityAddressAddressLine1
930 Winter Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite M-500
dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
443-2400
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
AVTE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28874513
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31115000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23491000
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
57615000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
98948000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1875000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1793000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
90605000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
124232000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
288000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
259000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
614000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
81000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2284000
CY2024Q3 us-gaap Assets
Assets
90959000
CY2023Q4 us-gaap Assets
Assets
127418000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
908000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2396000
CY2024Q3 avte Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
8948000
CY2023Q4 avte Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
14821000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
459000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
420000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
10315000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17637000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
81000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
255000
CY2024Q3 us-gaap Other Liabilities
OtherLiabilities
70000
CY2023Q4 us-gaap Other Liabilities
OtherLiabilities
70000
CY2024Q3 us-gaap Liabilities
Liabilities
10466000
CY2023Q4 us-gaap Liabilities
Liabilities
17962000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28867711
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27762703
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
3000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
307888000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
272640000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
224000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
237000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-227622000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-163424000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
80493000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
109456000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
90959000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
127418000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10328000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16884000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
51656000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46406000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7082000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4484000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16537000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12937000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
17410000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
21368000
us-gaap Operating Expenses
OperatingExpenses
68193000
us-gaap Operating Expenses
OperatingExpenses
59343000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-17410000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21368000
us-gaap Operating Income Loss
OperatingIncomeLoss
-68193000
us-gaap Operating Income Loss
OperatingIncomeLoss
-59343000
CY2024Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1183000
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1804000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4014000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4236000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-19000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1173000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1805000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3995000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4235000
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-16237000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-19563000
us-gaap Profit Loss
ProfitLoss
-64198000
us-gaap Profit Loss
ProfitLoss
-55108000
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-16237000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-19563000
us-gaap Profit Loss
ProfitLoss
-64198000
us-gaap Profit Loss
ProfitLoss
-55108000
CY2024Q3 us-gaap Debt Securities Trading Unrealized Gain Loss
DebtSecuritiesTradingUnrealizedGainLoss
307000
CY2023Q3 us-gaap Debt Securities Trading Unrealized Gain Loss
DebtSecuritiesTradingUnrealizedGainLoss
-22000
us-gaap Debt Securities Trading Unrealized Gain Loss
DebtSecuritiesTradingUnrealizedGainLoss
-13000
us-gaap Debt Securities Trading Unrealized Gain Loss
DebtSecuritiesTradingUnrealizedGainLoss
243000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15930000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19585000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-64211000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54865000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.13
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28863327
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28863327
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27640542
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27640542
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28572338
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28572338
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25872118
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25872118
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
109456000
CY2024Q1 us-gaap Debt Securities Trading Unrealized Loss
DebtSecuritiesTradingUnrealizedLoss
270000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
704000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4200000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-23186000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
90904000
CY2024Q2 us-gaap Debt Securities Trading Unrealized Loss
DebtSecuritiesTradingUnrealizedLoss
50000
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
23635000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
511000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
308000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3865000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-24775000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
94398000
CY2024Q3 us-gaap Debt Securities Trading Unrealized Gain
DebtSecuritiesTradingUnrealizedGain
307000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
22000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2003000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-16237000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
80493000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
126743000
CY2023Q1 us-gaap Debt Securities Trading Unrealized Gain
DebtSecuritiesTradingUnrealizedGain
265000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
223000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2384000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-16520000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
113095000
CY2023Q2 us-gaap Debt Securities Trading Unrealized Loss
DebtSecuritiesTradingUnrealizedLoss
22000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
44283000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
333000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
228000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3034000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-19025000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
141926000
CY2023Q3 us-gaap Debt Securities Trading Unrealized Gain
DebtSecuritiesTradingUnrealizedGain
28000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
95000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3237000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-19563000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
125723000
us-gaap Net Income Loss
NetIncomeLoss
-64198000
us-gaap Net Income Loss
NetIncomeLoss
-55108000
us-gaap Share Based Compensation
ShareBasedCompensation
10068000
us-gaap Share Based Compensation
ShareBasedCompensation
8655000
us-gaap Depreciation
Depreciation
274000
us-gaap Depreciation
Depreciation
68000
avte Accretion Of Discounts And Amortization Of Premiums On Investments Net
AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet
-1912000
avte Accretion Of Discounts And Amortization Of Premiums On Investments Net
AccretionOfDiscountsAndAmortizationOfPremiumsOnInvestmentsNet
-2118000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
82000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
128000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-789000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
70000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1488000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
880000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-4152000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
5948000
avte Increase Decrease In Operating Lease Asset And Liability
IncreaseDecreaseInOperatingLeaseAssetAndLiability
220000
avte Increase Decrease In Operating Lease Asset And Liability
IncreaseDecreaseInOperatingLeaseAssetAndLiability
9000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
332000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-114000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-60149000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41978000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
19683000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
96194000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
62583000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
102500000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
78000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
42900000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
6228000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
23635000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
44888000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
307000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
234000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
308000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
228000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1237000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
651000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
24873000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
45533000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7624000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9783000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23491000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22397000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
31115000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
32180000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
206000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
64000
CY2024Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
88700000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b) Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The preparation of the Company’s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. Accounting estimates and management judgements reflected in the consolidated financial statements include: normal recurring accruals, including the accrual for research and development expenses, stock-based compensation, fair value of investments, and operating lease right-of-use assets and lease liabilities. Estimates and assumptions are reviewed quarterly. Any revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</p>
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-16237000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-19563000
us-gaap Net Income Loss
NetIncomeLoss
-64198000
us-gaap Net Income Loss
NetIncomeLoss
-55108000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16237000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19563000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-64198000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-55108000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28863327
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28863327
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27640542
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27640542
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28572338
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28572338
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25872118
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25872118
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.13
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3714104
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5262586
CY2024Q3 us-gaap Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
57391000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
224000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
57615000
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss
98711000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
260000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
23000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
98948000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
13400000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
14000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
7586000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
9000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
20986000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
23000
CY2024Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2023Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2024Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent
300000
CY2023Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent
600000
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
993000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1168000
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
882000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
250000
CY2023Q4 avte Prepaid Research And Development
PrepaidResearchAndDevelopment
375000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1875000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1793000
CY2024Q3 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Inception To Date
RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate
46
CY2024Q3 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Inception To Date Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent
0.90
us-gaap Restructuring And Related Cost Incurred Cost
RestructuringAndRelatedCostIncurredCost
6400000
us-gaap Payments For Restructuring
PaymentsForRestructuring
2400000
CY2024Q3 us-gaap Restructuring And Related Cost Expected Cost Remaining1
RestructuringAndRelatedCostExpectedCostRemaining1
4000000.0
CY2024Q3 avte Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
4704000
CY2023Q4 avte Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
9363000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3952000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4368000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
292000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1090000
CY2024Q3 avte Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
8948000
CY2023Q4 avte Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
14821000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
316000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
242000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
558000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
18000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
540000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
459000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
420000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
81000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
255000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
540000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
675000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y1M6D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y6M
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.064
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060
us-gaap Operating Lease Payments
OperatingLeasePayments
380000
us-gaap Operating Lease Payments
OperatingLeasePayments
323000
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
115000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
111000
us-gaap Operating Lease Cost
OperatingLeaseCost
343000
us-gaap Operating Lease Cost
OperatingLeaseCost
332000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
165000
CY2024Q3 us-gaap Lease Cost
LeaseCost
115000
CY2023Q3 us-gaap Lease Cost
LeaseCost
111000
us-gaap Lease Cost
LeaseCost
508000
us-gaap Lease Cost
LeaseCost
332000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 avte Number Of Votes For Each Share Of Common Stock
NumberOfVotesForEachShareOfCommonStock
1
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7097427
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5230344
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.66
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M28D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
49728000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1489191
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
19.70
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
265482
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.67
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
2739949
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
18.84
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3714104
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.91
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y11M23D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
12000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
2791181
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
12.06
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P3Y11M12D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
12000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
14.92
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2003000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3237000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10068000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8655000
CY2024Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2003000
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
3237000
us-gaap Share Based Compensation
ShareBasedCompensation
10068000
us-gaap Share Based Compensation
ShareBasedCompensation
8655000

Files In Submission

Name View Source Status
0001798749-24-000059-index-headers.html Edgar Link pending
0001798749-24-000059-index.html Edgar Link pending
0001798749-24-000059.txt Edgar Link pending
0001798749-24-000059-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20240930.xsd Edgar Link pending
tmb-20240930x10q.htm Edgar Link pending
tmb-20240930xex10d1.htm Edgar Link pending
tmb-20240930xex10d1001.jpg Edgar Link pending
tmb-20240930xex31d1.htm Edgar Link pending
tmb-20240930xex31d2.htm Edgar Link pending
tmb-20240930xex32d1.htm Edgar Link pending
tmb-20240930xex32d2.htm Edgar Link pending
tmb-20240930_cal.xml Edgar Link unprocessable
tmb-20240930_def.xml Edgar Link unprocessable
tmb-20240930_lab.xml Edgar Link unprocessable
tmb-20240930_pre.xml Edgar Link unprocessable
tmb-20240930x10q_htm.xml Edgar Link completed